Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureTasanee Onkoksoong, Sunisa Prasopporn, Sith Sathornsumetee, Uraiwan Panich
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Management of glioblastoma: State of the art and future directions
10.3322/caac.21613 · 2020
Management of glioblastoma: State of the art and future directions
10.3322/caac.21613 · 2020
Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: Effects on cell death, self-renewal, and invasion
10.1186/s12885-023-11271-w · 2023
Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: Effects on cell death, self-renewal, and invasion
10.1186/s12885-023-11271-w · 2023
Glioblastoma: Current status, emerging targets, and recent advances
10.1021/acs.jmedchem.1c01946 · 2022
Glioblastoma: Current status, emerging targets, and recent advances
10.1021/acs.jmedchem.1c01946 · 2022
The role of hypoxia in glioblastoma invasion
10.3390/cells6040045 · 2017
The role of hypoxia in glioblastoma invasion
10.3390/cells6040045 · 2017
The clinical importance of assessing tumor hypoxia: Relationship of tumor hypoxia to prognosis and therapeutic opportunities
10.1089/ars.2013.5378 · 2014
The clinical importance of assessing tumor hypoxia: Relationship of tumor hypoxia to prognosis and therapeutic opportunities
10.1089/ars.2013.5378 · 2014
Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis
10.1038/s41419-018-1176-7 · 2018
Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis
10.1038/s41419-018-1176-7 · 2018
Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review
10.20517/cdr.2020.79 · 2021
Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review
10.20517/cdr.2020.79 · 2021
CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway
10.1038/s41419-023-05788-y · 2023
CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway
10.1038/s41419-023-05788-y · 2023
Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing
10.1074/jbc.m001914200 · 2000
Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing
10.1074/jbc.m001914200 · 2000
Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species
10.1152/ajplung.00014.2002 · 2002
Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species
10.1152/ajplung.00014.2002 · 2002
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
10.1016/j.cmet.2005.05.001 · 2005
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
10.1016/j.cmet.2005.05.001 · 2005
Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation
10.1093/emboj/20.18.5197 · 2001
Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation
10.1093/emboj/20.18.5197 · 2001
Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha
10.1128/mcb.25.15.6415-6426.2005 · 2005
Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha
10.1128/mcb.25.15.6415-6426.2005 · 2005
Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2
10.1128/mcb.24.16.7130-7139.2004 · 2004
Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2
10.1128/mcb.24.16.7130-7139.2004 · 2004
Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer
10.1038/s12276-024-01180-8 · 2024
Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer
10.1038/s12276-024-01180-8 · 2024
Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1α
10.1002/ijc.28699 · 2014
Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1α
10.1002/ijc.28699 · 2014
Knockdown of Nrf2 radiosensitizes glioma cells by inducing redox stress and apoptosis in hypoxia
10.21037/tcr-22-1420 · 2022
Knockdown of Nrf2 radiosensitizes glioma cells by inducing redox stress and apoptosis in hypoxia
10.21037/tcr-22-1420 · 2022
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
10.1093/carcin/bgn095 · 2008
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
10.1093/carcin/bgn095 · 2008
The role of PGC1α in cancer metabolism and its therapeutic implications
10.1158/1535-7163.mct-15-0621 · 2016
The role of PGC1α in cancer metabolism and its therapeutic implications
10.1158/1535-7163.mct-15-0621 · 2016
Nrf2 as a regulator of energy metabolism and mitochondrial function
10.1002/1873-3468.14993 · 2024
Nrf2 as a regulator of energy metabolism and mitochondrial function
10.1002/1873-3468.14993 · 2024
Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells
10.1074/jbc.m117.792838 · doi-reference
6-Gingerol induced apoptosis and cell cycle arrest in glioma cells via MnSOD and ERK phosphorylation modulation
10.4062/biomolther.2024.084 · doi-reference
TGF-β and hypoxia/reoxygenation promote radioresistance of A549 lung cancer cells through activation of Nrf2 and EGFR
10.1155/2016/6823471 · doi-reference
Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma
10.1038/s41420-022-01230-y · doi-reference
EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance
10.3390/cancers13112748 · doi-reference
TGF-β signaling and resistance to cancer therapy
10.3389/fcell.2021.786728 · doi-reference
EGFR and NF-κB: Partners in cancer
10.1016/j.molmed.2015.04.001 · doi-reference
Brusatol inhibits HIF-1 signaling pathway and suppresses glucose uptake under hypoxic conditions in HCT116 cells
10.1038/srep39123 · doi-reference
Nrf2 activation supports cell survival during hypoxia and hypoxia/reoxygenation in cardiomyoblasts; the roles of reactive oxygen and nitrogen species
10.1016/j.redox.2013.08.002 · doi-reference
Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia
10.18632/oncotarget.7406 · doi-reference
Natural Nrf2 inhibitors: A review of their potential for cancer treatment
10.7150/ijbs.82401 · doi-reference
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer
10.1016/j.redox.2023.102726 · doi-reference
Exploring the role of Nrf2 signaling in glioblastoma multiforme
10.1007/s12672-022-00556-4 · doi-reference
The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism
10.1016/j.gendis.2016.11.003 · doi-reference
The potential role of HIF on tumour progression and dissemination
10.1002/ijc.28889 · doi-reference
Hypoxia signaling in human health and diseases: Implications and prospects for therapeutics
10.1038/s41392-022-01080-1 · doi-reference
HIF1α/HIF2α-Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR-PI3K/AKT signalling pathway with positive feedback under hypoxia
10.1038/s41419-021-03598-8 · doi-reference
Mechanism of hypoxia-induced NF-kappaB
10.1128/mcb.00409-10 · doi-reference
Integrated analysis identified core signal pathways and hypoxic characteristics of human glioblastoma
10.1111/jcmm.14507 · doi-reference
Brusatol inhibits proliferation and invasion of glioblastoma by down-regulating the expression of ECM1
10.3389/fphar.2021.775680 · doi-reference
Oxidative stress in cancer cell metabolism
10.3390/antiox10050642 · doi-reference
Live-cell imaging Unveils stimulus-specific dynamics of Nrf2 activation in UV-exposed melanoma cells: Implications for antioxidant compound screening
10.1016/j.freeradbiomed.2023.12.007 · doi-reference
Photoprotection by dietary phenolics against melanogenesis induced by UVA through Nrf2-dependent antioxidant responses
10.1016/j.redox.2015.12.006 · doi-reference
Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica
10.1016/j.biopha.2022.114134 · doi-reference
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method
10.1006/meth.2001.1262 · doi-reference
The protective effect of polyherbal formulation, harak formula, on UVA-induced photoaging of human dermal fibroblasts and mouse skin via promoting Nrf2-regulated antioxidant defense
10.3389/fphar.2021.649820 · doi-reference
The acquired vulnerability caused by CDK4/6 inhibition promotes drug synergism between oxaliplatin and palbociclib in cholangiocarcinoma
10.3389/fonc.2022.877194 · doi-reference
Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma
10.4172/1948-5956.1000410 · doi-reference
Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2
10.1016/j.freeradbiomed.2014.11.003 · doi-reference
Brusatol overcomes chemoresistance through inhibition of protein translation
10.1002/mc.22609 · doi-reference
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
10.1073/pnas.1014275108 · doi-reference